title: [Anti-lymphoma effects of ZnPcS2P2-mediated photodynamic therapy combined with mGM-CSF and mB7.1 gene-modified vaccine].
abstract: OBJECTIVE
  To explore the anti-lymphoma efficacy of ZnPcS(2)P(2)-mediated photodynamic therapy(PDT) combined with mGM-CSF and mB7.1 gene-modified high-tumorigenicity lymphoma cells (EL-4 cells) in C57BL/6 mice.
  
  
  METHODS
  EL-4/pLXSN, EL-4/GM and EL-4/B7 were generated by consecutive infection of EL-4 cells with respective retroviruses, i.e pLXSN, pLXSNmGM-CSF and pLXSNmB7.1. The total of 40 C57BL/6 mice receiving the inoculation of EL-4 cells five days before the experiment, were randomly divided into five groups with 8 in each group: control group (without any treatment), ZnPc-PDT control group, ZnPc-PDT+EL-4/pLXSN control group, EL-4/B7+EL-4/GM control group and ZnPc-PDT+EL-4/B7+EL-4/GM group. The procedure of PDT was carried out as follows: the mice were injected with ZnPcS(2)P(2) via the lateral tail veins, and 4 h later the tumor was irradiated with 670 nm laser. The size of tumor node was measured every other day. The survival time and relative tumor volume(RTV) of each group were compared. The histological morphology of tumor was observed.
  
  
  RESULTS
  Compared with each control group, the survival time of experimental group was significantly prolonged (P<0.01). Moreover, difference of the survival time was measured between ZnPc-PDT control group and EL-4/B7+EL-4/GM control group (P=0.01).
  
  
  CONCLUSIONS
  Tumor-localized immune stimulation by mGM-CSF and mB7.1 remarkably enhanced ZnPc-PDT-elicited anti-lymphoma potency.
authors.affiliation: Fujian Institute of Hemapathy, Union Hospital, Fujian Medical University, Fuzhou 350001, China. huifanghuang1971@163.com
authors.forename: Hui-fang
authors.initials: HF
authors.lastname: Huang
authors.forename: Yuan-zhong
authors.initials: YZ
authors.lastname: Chen
authors.forename: Yong
authors.initials: Y
authors.lastname: Wu
authors.forename: Nai-nong
authors.initials: NN
authors.lastname: Li
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D015316:Genetic Therapy / Q000379:methods*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D007211:Indoles / Q000737:chemistry*; D008223:Lymphoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D041681:NIH 3T3 Cells; D009942:Organometallic Compounds / Q000737:chemistry*; D010778:Photochemotherapy / Q000379:methods
chemical_list: D019496:Cancer Vaccines; D007211:Indoles; D009942:Organometallic Compounds; C063072:zinc(II) phthalocyanine trisulfonic acid; D016178:Granulocyte-Macrophage Colony-Stimulating Factor